PharmGen Science, Inc. (KRX:004720)
South Korea · Delayed Price · Currency is KRW 3,030.00
+5.00 (0.17%)
Sep 14, 2026, 1:02 PM KST
PharmGen Science Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 68,403 | 74,179 | 111,355 | 105,470 | 159,511 | 165,783 | |
Market Cap Growth | -19.74% | -33.39% | 5.58% | -33.88% | -3.78% | 123.51% |
Enterprise Value | 73,749 | 78,578 | 127,335 | 126,753 | 178,736 | 154,760 |
Last Close Price | 3025.00 | 4090.00 | 6200.00 | 6680.00 | 10500.00 | 11300.00 |
Price Ratios
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
PE Ratio | 580.92 | 26.58 | 18.29 | 1.51 | 4.91 | 17.98 |
PS Ratio | 0.40 | 0.43 | 0.67 | 0.70 | 1.45 | 1.72 |
PB Ratio | 0.28 | 0.30 | 0.48 | 0.51 | 1.26 | 1.98 |
P/TBV Ratio | 0.28 | 0.30 | 0.48 | 0.51 | 1.26 | 1.99 |
P/FCF Ratio | - | 50.61 | 35.09 | - | - | - |
P/OCF Ratio | - | 31.11 | 20.47 | - | 20.49 | 61.96 |
EV Ratios
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
EV/Sales Ratio | 0.43 | 0.46 | 0.76 | 0.84 | 1.63 | 1.60 |
EV/EBITDA Ratio | 10.64 | 5.15 | 9.52 | 11.76 | - | 146.36 |
EV/EBIT Ratio | 32.02 | 7.40 | 13.95 | 17.10 | - | - |
EV/FCF Ratio | - | 53.62 | 40.13 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Debt / Equity Ratio | 0.08 | 0.16 | 0.16 | 0.19 | 0.38 | 0.26 |
Debt / EBITDA Ratio | 1.36 | 2.55 | 2.84 | 3.66 | - | 20.24 |
Debt / FCF Ratio | - | 26.60 | 11.96 | - | - | - |
Net Debt / Equity Ratio | 0.02 | 0.00 | 0.00 | 0.10 | 0.11 | -0.11 |
Net Debt / EBITDA Ratio | 0.37 | 0.04 | 0.04 | 1.82 | -7.70 | -8.55 |
Net Debt / FCF Ratio | -2.75 | 0.37 | 0.17 | -1.75 | -0.60 | 5.44 |
Asset Turnover | 0.50 | 0.49 | 0.51 | 0.56 | 0.62 | 0.82 |
Inventory Turnover | 2.28 | 2.41 | 3.32 | 3.87 | 3.11 | 2.85 |
Quick Ratio | 1.26 | 1.19 | 1.16 | 0.70 | 0.76 | 1.38 |
Current Ratio | 2.08 | 1.69 | 1.51 | 1.03 | 1.09 | 1.99 |
Return on Equity (ROE) | 0.05% | 1.16% | 2.77% | 41.95% | 30.80% | 13.05% |
Return on Assets (ROA) | 1.76% | 1.88% | 1.73% | 1.72% | -1.73% | -1.01% |
Return on Invested Capital (ROIC) | 3.83% | 4.40% | 2.86% | 3.14% | -3.55% | -2.30% |
Return on Capital Employed (ROCE) | 3.30% | 3.60% | 3.30% | 3.00% | -3.30% | -1.90% |
Yields
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Earnings Yield | 0.17% | 3.76% | 5.47% | 66.43% | 20.35% | 5.56% |
FCF Yield | -2.84% | 1.98% | 2.85% | -10.63% | -14.40% | -1.00% |
Buyback Yield / Dilution | -0.11% | -4.74% | 3.68% | -16.09% | -23.81% | -30.15% |